Literature DB >> 33633189

Novel method for screening functional antibody with comprehensive analysis of its immunoliposome.

Shusei Hamamichi1, Takeshi Fukuhara2,3, Izumi O Umeda4,5, Hirofumi Fujii5, Nobutaka Hattori6,7.   

Abstract

Development of monoclonal antibody is critical for targeted drug delivery because its characteristics determine improved therapeutic efficacy and reduced side-effect. Antibody therapeutics target surface molecules; hence, internalization is desired for drug delivery. As an antibody-drug conjugate, a critical parameter is drug-to-antibody ratio wherein the quantity of drugs attached to the antibody influences the antibody structure, stability, and efficacy. Here, we established a cell-based immunotoxin screening system to facilitate the isolation of functional antibodies with internalization capacities, and discovered an anti-human CD71 monoclonal antibody. To overcome the limitation of drug-to-antibody ratio, we employed the encapsulation capacity of liposome, and developed anti-CD71 antibody-conjugated liposome that demonstrated antigen-antibody dependent cellular uptake when its synthesis was optimized. Furthermore, anti-CD71 antibody-conjugated liposome encapsulating doxorubicin demonstrated antigen-antibody dependent cytotoxicity. In summary, this study demonstrates the powerful pipeline to discover novel functional antibodies, and the optimal method to synthesize immunoliposomes. This versatile technology offers a rapid and direct approach to generate antibodies suitable for drug delivery modalities.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33633189      PMCID: PMC7907096          DOI: 10.1038/s41598-021-84043-w

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  40 in total

Review 1.  Building better monoclonal antibody-based therapeutics.

Authors:  George J Weiner
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

Review 2.  The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect.

Authors:  Jun Fang; Hideaki Nakamura; Hiroshi Maeda
Journal:  Adv Drug Deliv Rev       Date:  2010-05-02       Impact factor: 15.470

3.  Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target.

Authors:  Y Joy Yu; Yin Zhang; Margaret Kenrick; Kwame Hoyte; Wilman Luk; Yanmei Lu; Jasvinder Atwal; J Michael Elliott; Saileta Prabhu; Ryan J Watts; Mark S Dennis
Journal:  Sci Transl Med       Date:  2011-05-25       Impact factor: 17.956

Review 4.  Transferrin receptor 1 in cancer: a new sight for cancer therapy.

Authors:  Ying Shen; Xin Li; Dandan Dong; Bin Zhang; Yanru Xue; Peng Shang
Journal:  Am J Cancer Res       Date:  2018-06-01       Impact factor: 6.166

5.  DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.

Authors:  Yusuke Ogitani; Tetsuo Aida; Katsunobu Hagihara; Junko Yamaguchi; Chiaki Ishii; Naoya Harada; Masako Soma; Hiromi Okamoto; Masataka Oitate; Shingo Arakawa; Takehiro Hirai; Ryo Atsumi; Takashi Nakada; Ichiro Hayakawa; Yuki Abe; Toshinori Agatsuma
Journal:  Clin Cancer Res       Date:  2016-03-29       Impact factor: 12.531

6.  Targeting transferrin receptors at the blood-brain barrier improves the uptake of immunoliposomes and subsequent cargo transport into the brain parenchyma.

Authors:  Kasper Bendix Johnsen; Annette Burkhart; Fredrik Melander; Paul Joseph Kempen; Jonas Bruun Vejlebo; Piotr Siupka; Morten Schallburg Nielsen; Thomas Lars Andresen; Torben Moos
Journal:  Sci Rep       Date:  2017-09-04       Impact factor: 4.379

Review 7.  Impairment of the Developing Human Brain in Iron Deficiency: Correlations to Findings in Experimental Animals and Prospects for Early Intervention Therapy.

Authors:  Veronika Markova; Charlotte Holm; Anja Bisgaard Pinborg; Lars Lykke Thomsen; Torben Moos
Journal:  Pharmaceuticals (Basel)       Date:  2019-08-14

Review 8.  Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles.

Authors:  Akhand Pratap Singh; Arpan Biswas; Aparna Shukla; Pralay Maiti
Journal:  Signal Transduct Target Ther       Date:  2019-08-30

9.  A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II.

Authors:  Hiroyuki Sonoda; Hideto Morimoto; Eiji Yoden; Yuri Koshimura; Masafumi Kinoshita; Galina Golovina; Haruna Takagi; Ryuji Yamamoto; Kohtaro Minami; Akira Mizoguchi; Katsuhiko Tachibana; Tohru Hirato; Kenichi Takahashi
Journal:  Mol Ther       Date:  2018-03-06       Impact factor: 11.454

10.  A novel immunotoxin reveals a new role for CD321 in endothelial cells.

Authors:  Takeshi Fukuhara; Jia Kim; Shintaro Hokaiwado; Makiko Nawa; Hayato Okamoto; Tomohiko Kogiso; Tetsuro Watabe; Nobutaka Hattori
Journal:  PLoS One       Date:  2017-10-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.